Day: July 23, 2024

OLNEY, Md., July 23, 2024 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq-SASR), the parent company of Sandy Spring Bank, reported net income of $22.8 million ($0.51 per diluted common share) for the quarter ended June 30, 2024, compared to net income of $20.4 million ($0.45 per diluted common share) for the first quarter of 2024 and $24.7 million ($0.55 per diluted common share) for the second quarter of 2023. Current quarter’s core earnings were $24.4 million ($0.54 per diluted common share), compared to $21.9 million ($0.49 per diluted common share) for the quarter ended March 31, 2024 and $27.1 million ($0.60 per diluted common share) for the quarter ended June 30, 2023. Core earnings exclude the after-tax impact of amortization of intangibles, investment securities gains or losses and other non-recurring or extraordinary...

Lassila & Tikanoja plc Investor News 23 July 2024 2.00 pm Lassila & Tikanoja plc will publish Half-Year Report January-June on 7 August 2024 Lassila & Tikanoja plc will publish Half-Year Report January-June on Wednesday 7 August 2024 at 8.00 am. After publication, the release will be available on the company’s website at www.lt.fi/en. Lassila & Tikanoja will host a webcast for analysts, investors and media on 7 August 2024 at 10.30 am EET. The presentation material will be published on the company’s website. The English language briefing will be hosted by CEO Eero Hautaniemi and CFO Joni Sorsanen. Conference call You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. https://palvelu.flik.fi/teleconference/?id=50049975 Webcast...

MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce that its subsidiary Drosrite International (DI) will henceforth be named PyroGenesis International. The Company’s Board of Directors is currently reviewing various locations in the United States where PyroGenesis International could be located. As announced previously in a news release on July 8, 2024, the Company has purchased 100% control of DI, a US-based private company. DI had already been, on an accounting basis, a subsidiary of...

JUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced that it will report its financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, August 14, 2024 and host a conference call and webcast at 5 p.m. ET to discuss the results. The call will be hosted by Tony Aquila, Investor, Executive Chairman and Chief Executive Officer, Greg Ethridge, Chief Financial Officer and Ramesh Murthy, Senior Vice President, Finance and Chief Accounting Officer. Conference Call and Webcast DetailsA slide presentation and webcast link will be posted on the Canoo Investor Relations website at investors.canoo.com. To listen to the conference call by phone, dial 1-877-407-9169 in the U.S., or 1-201-493-6755 Internationally. The Conference...

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer’s Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 Presentations TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95594)Presenting Author: Arthur J. Mayorga, Ph.D., Vice President, Clinical...

Reiterating cash runway of > 2 years JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies. “We are pleased to have completed these important studies in refractory invasive fungal infections, for which there remains an urgent need to deliver new solutions and combat growing resistance,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “Work continues...

PARIS, July 23, 2024 (GLOBE NEWSWIRE) — Constellium (NYSE: CSTM) announced today that its facility in Muscle Shoals, Alabama has been selected by the U.S. Department of Defense (DoD) for an investment of $23 million under Title III, Defense Production Act to rebuild its Direct Chill aluminium casting center. The funding was awarded via the Defense Production Act Investments (DPAI) Program. DPAI is overseen by the Manufacturing Capability Expansion and Investment Program (MCEIP) in the Office of the Assistant Secretary of Defense for Industrial Base Policy. Constellium will use the funds to install state-of-the-art casting equipment on the site of a dismantled casting center intended to add up to 300 million pounds of annual casting capacity. With this added capacity, the plant expects to increase its recycled input, reduce its...